BridgeMD
New treatment option for Acute Liver Failure
Official title ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF
ClinicalTrials.gov ID: NCT07329036
What this study is testing
- What it's testing
- The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Adult patient, age ≥18 years
- Expressed consent to the inclusion
- Patient hospitalized on ICU with ALF or ACLF diagnosis
- Recently meeting the inclusion to liver transplantation
- Present on a waiting list to liver transplant
You likely can't join if
- Disagreement with the study
- Infaust prognosis with expected survival less than 24 hours
- Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA...
- Advanced oncological disease (expected life expectancy below 6 months)
- Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according
See the full eligibility criteria
- Adult patient, age ≥18 years
- Expressed consent to the inclusion
- Patient hospitalized on ICU with ALF or ACLF diagnosis
- Recently meeting the inclusion to liver transplantation
- Present on a waiting list to liver transplant
- Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care
- Disagreement with the study
- Infaust prognosis with expected survival less than 24 hours
- Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
- Advanced oncological disease (expected life expectancy below 6 months)
- Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according
The study team makes the final eligibility decision.
Where it's taking place
- Prague, Czechia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Prague, Czechia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.